You are here: Industry Insights > CAR-T

News List

Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D fiercebiotech
November 14, 2017
Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.
FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat fiercebiotech
November 08, 2017
The FDA has lifted the clinical hold it placed on Cellectis’ CAR-T trials in September following the death of a patient.
Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell pharmafile
November 01, 2017
Novartis has submitted a second marketing application for the therapy with the US regulator.
Explore the Research Progress of Over 2,400 Gene Therapies in the World en-cphi.cn
September 11, 2017
CAR-T and Other Immunotherapies Encounter Obstructions at Their Beginning
Takeda and Noile-Immune to jointly develop new CAR-T immunotherapies for cancer pharmaceufical-technology
September 06, 2017
Takeda Pharmaceutical has entered a collaboration with Noile-Immune Biotech to develop next-generation chimeric antigen receptor T-cell (CAR-T) therapy for solid tumours.
Noile-Immune signs CAR-T collaboration with Japanese pharma major biospectrumasia
September 06, 2017
Noile-Immune signs CAR-T collaboration with Japanese pharma major The next generation CAR-T cell therapy was developed by Professor Koji Tamada at Yamaguchi University and Noile-Immune has an exclusive license for this platform technology.
Novartis meeting before CAR-T approval leaves concerned about pricing fiercepharma
August 31, 2017
How expensive will Novartis' CAR-T cancer treatment be?
Novartis crosses FDA finish line with monumental CAR-T leukemia approval fiercepharma
August 31, 2017
Novartis won FDA approval for its CAR-T drug Kymriah on Wednesday.
‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments fiercebiotech
August 31, 2017
Fred Hutch scientists are using nanoparticles to improve engineered cells such as CAR-T cells.
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight fiercepharma
August 30, 2017
Gilead announced an $11.9 purchase of Kite Pharma on Monday, picking up the promising CAR-T drug Axi-Cel.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page